- JP-listed companies
- RaQualia Pharma Inc.
- Income statement
RaQualia Pharma Inc. (4579) Income statement
Market cap
¥22.3B
P/E ratio
-331.8x
Rakuoria Drug Discovery develops new pharmaceutical compounds through early-stage research and clinical trials, then licenses them to major pharmaceutical companies for revenue.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 684 | 29 | 228 | 154 | 146 | 705 | 1,419 | 745 | 1,703 | 1,107 | 2,776 | 2,918 | 1,901 | 3,108 | 3,980 |
| Revenue growth (%) | - | ||||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating income | - | - | - | -2,123 | -1,865 | -760 | -150 | -1,075 | -16 | -486 | 708 | 866 | -337 | -213 | 484 |
| Income before tax | -1,906 | -2,891 | -1,820 | -1,942 | -1,795 | -721 | -81 | -1,065 | 22 | -528 | 864 | 904 | -293 | -362 | 438 |
| Pretax margin (%) | -278.6 | -9,977.5 | -799.5 | -1,262.1 | -1,233.8 | -102.2 | -5.7 | -143 | 1.3 | -47.7 | 31.1 | 31 | -15.4 | -11.6 | 11 |
| Provision for income taxes | - | - | - | - | 6 | 5 | -2 | 26 | 22 | 79 | 125 | 128 | 30 | 137 | 165 |
| Effective tax rate (%) | - | - | - | - | |||||||||||
| Net income | -1,916 | -2,905 | -1,137 | -465 | -1,854 | -728 | -58 | -1,105 | 5 | -607 | 756 | 723 | -324 | -495 | 273 |
| Earnings per share | -172.85 | -219 | -84.83 | -33.23 | -116.45 | -38.8 | -2.99 | -54.23 | 0.26 | -28.97 | 36.07 | 34.5 | -14.98 | -22.87 | 11.53 |
| Diluted EPS | - | - | - | - | - | - | - | - | 0.26 | - | 36.04 | 34.47 | - | 2.6 | 11.36 |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |